

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI162886

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
2seventy bio, Inc.	04/01/2024
RECEIVING PARTY DATA	
Company Name:	Regeneron Pharmaceuticals, Inc.
Street Address:	777 OLD SAW MILL RIVER RD
City:	TARRYTOWN
State/Country:	NEW YORK
Postal Code:	10591-6707
PROPERTY NUMBERS Total: 9	
Property Type	Number
Application Number:	61859697
Application Number:	61934092
Application Number:	14908734
Application Number:	14608098
Application Number:	16219640
Application Number:	16540673
Application Number:	16573254
Application Number:	17675246
Application Number:	18054223
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174496500
Email:	mlombardo@mccarter.com
Correspondent Name:	Marcie Clarke
Address Line 1:	McCarter & English LLP
Address Line 2:	265 Franklin Street
Address Line 4:	Boston, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	137080-001xx
NAME OF SUBMITTER:	Michelle Lombardo

PATENT

SIGNATURE:	Michelle Lombardo
DATE SIGNED:	04/12/2024
Total Attachments: 12 source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page1.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page2.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page3.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page4.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page5.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page6.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page7.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page8.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page9.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page10.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page11.tif source=Project Snowbird - Patent Assignment Agreement (EXECUTED 4.1.24)#page12.tif	

EXECUTION VERSION

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this “Assignment”) is entered into effective as of April 1, 2024 by and between 2seventy bio, Inc., a Delaware corporation (“Assignor”), and Regeneron Pharmaceuticals, Inc., a New York corporation (“Assignee”, together with Assignor, the “Parties”). Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Asset Purchase Agreement (defined below).

WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement, dated as of January 29, 2024 (as may be amended or restated from time to time, the “Asset Purchase Agreement”), pursuant to which Assignor has agreed to, among other things, sell, assign, transfer, convey, and deliver to Assignee certain Intellectual Property, as more fully described in the Asset Purchase Agreement, on the terms and subject to the conditions set forth in the Asset Purchase Agreement; and

WHEREAS, such Intellectual Property includes, without limitation, the Patents set forth on Annex A hereto (collectively, the “Transferred Patents”).

NOW, THEREFORE, pursuant to the Asset Purchase Agreement, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. Assignment. Assignor hereby sells, assigns, transfers and delivers to Assignee, and Assignee hereby purchases and acquires from Assignor, all rights, titles, and interests of Assignor in, to and under the Transferred Patents in the United States and in all foreign countries (including, without limitation, all rights therein provided by international conventions and treaties), including, without limitation, any priority applications, applications for patent, patents, reissues, divisions, continuations, continuations-in-part, extensions, re-examinations and foreign equivalents thereof, all rights to claim priority thereto or therefrom, and all rights therein provided by international treaties and conventions, together with all associated income, royalties, damages or payments accrued, due or payable as of the Effective Date or thereafter and including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Transferred Patents, with the right to sue for, and collect the same, in each case, for Assignee’s own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made. Assignee acknowledges that Assignor makes no representations or warranties with respect to the Transferred Patents except as specifically set forth in the Asset Purchase Agreement.

2. Recordation. Assignor hereby authorizes and requests that the United States Patent and Trademark Office Commissioner for Patents (the “USPTO”) and any other applicable Governmental Authority or registrar (including any applicable foreign or international office or registrar) record this Assignment and record Assignee as the assignee and owner of the Transferred Patents. Assignor further authorizes and requests the USPTO and any other applicable Governmental Authority or registrar (including any applicable foreign or international office or registrar) to transfer all registrations and registration applications included in the Transferred Patents to Assignee as purchaser of Assignor’s rights, titles and interests therein, in accordance with this Assignment, and to issue to Assignee all registrations that may issue with respect to any applications for registration of patent rights included in such Transferred Patents.

3. Further Assurances.

3.1 Upon Assignee's reasonable request and without further compensation, Assignor shall execute, acknowledge and deliver all such other instruments and documents and shall take all such other actions reasonably necessary or required by Law to consummate and make fully effective the transaction contemplated by this Assignment.

3.2 If Assignee is unable for any reason to secure any of Assignor's signatures to any document required to file, prosecute, register or memorialize the assignment of any rights under any Transferred Patents as provided under this Assignment, then Assignor hereby irrevocably designates and appoints Assignee and Assignee's duly authorized officers and agents as Assignor's agents and attorneys-in-fact to act for and on each of Assignor's behalf and instead of Assignor to take all lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, issuance, and enforcement of rights under such Transferred Patents, all with the same legal force and effect as if executed by Assignor. The foregoing is deemed a power coupled with an interest and is irrevocable.

4. No Third-Party Beneficiaries. Nothing in this Assignment, express or implied, is intended or shall be construed to confer upon, or to give to, any Person other than Assignee and its successors and assigns any remedy or claim under or by reason of this Assignment or any terms, covenants or conditions hereof, and all the terms, covenants and conditions, promises and agreements in this Assignment contained shall be for the sole and exclusive benefit of Assignee and its respective successors and assigns.

5. Interpretation. This Assignment is intended to implement the provisions of the Asset Purchase Agreement, is expressly subject to the terms and conditions thereof, and shall not be construed to enhance, extend or limit the representations and warranties, rights, obligations or remedies of either Party. In case of any conflict or inconsistency between the terms and conditions of this Assignment and the terms and conditions of the Asset Purchase Agreement, the terms and conditions of the Asset Purchase Agreement shall govern.

6. Amendment. Except as otherwise provided herein, no amendment, modification or supplement of any provision of this Assignment shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party.

7. Waiver. No provision of this Assignment shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.

8. Governing Law. This Assignment shall be governed and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice of law provisions thereof that would result in the application of the Law of any jurisdiction other than Delaware. The Parties hereby irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware sitting in the New Castle County (or, only if the Court of Chancery of the State of Delaware declines to accept or does not have jurisdiction over a particular matter, any federal or other state court sitting in New Castle County within the State of Delaware), and the appellate courts having jurisdiction of appeals in such courts, in each case, over any dispute arising under this Assignment and each Party hereby irrevocably agrees that all claims in respect of this Assignment shall be heard and determined in such courts. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable Law, any objection which they may now or hereafter have to the laying of venue of any such claim brought in such court or any defense of inconvenient forum for the

maintenance of such claim. Each of the Parties agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

9. Counterparts. This Agreement may be executed in one or more counterparts, and signature pages may be delivered by portable document format (PDF), DocuSign or any other electronic signature complying with the U.S. federal ESIGN Act of 2000, the Delaware Uniform Electronic Transactions Act, and any other applicable Law, each of which shall be deemed an original, but all of which will be considered one and the same agreement and will become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party, it being understood that all Parties need not sign the same counterpart.

[Signature page follows]

IN WITNESS WHEREOF, Assignor intending to be legally bound has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date.

ASSIGNOR:

2SEVENTY BIO, INC.

By: _____

Name: Nick Leschly

Title: President and Chief Executive Officer

Witness:

Ana Fernandez 03-19-24
Name and date

Witness:


[Signature] 3-19-24
Name and date

COMMONWEALTH OF
Massachusetts)

) SS.

COUNTY OF
Middlesex)

On this 17th day of March, 2024, there appeared before me Nick Leschly
personally known to me, who acknowledged that he/she signed the foregoing Assignment as
his/her voluntary act and deed on behalf and with full authority of 2seventy bio, Inc.



Kelley J. Dolliver
Notary Public

[Signature Page to Patent Assignment Agreement]

IN WITNESS WHEREOF, Assignee intending to be legally bound has caused this Assignment to be executed by its duly authorized representatives as of the Effective Date.

ASSIGNEE:


REGENERON PHARMACEUTICALS, INC.

By: 

Name: Nouhad Hussein

Title: Senior Vice President, Head of Business
Development and Corporate Strategy

Witness: Paige Cooperman

 3/11/2024
Name and date

Witness: Victoria A. Thiele - Gambino

 3/11/2024
Name and date


STATE OF New York)

) SS.

COUNTY OF Westchester

On this 11th day of March, 2024, there appeared before me Nouhad Hussein,
personally known to me, who acknowledged that he/she signed the foregoing Assignment as
his/her voluntary act and deed on behalf and with full authority of Regeneron Pharmaceuticals,
Inc.

NANCY FERRARA
NOTARY PUBLIC, STATE OF NEW YORK
NO. 03-4823560
QUALIFIED IN WESTCHESTER COUNTY
COMMISSION EXPIRES JUNE 30, 2027


Notary Public

[Signature Page to Patent Assignment Agreement]

PATENT
REEL: 067092 FRAME: 0817

Exhibit A

Transferred Patents

[Exhibit A to Patent Assignment Agreement]

PATENT
REEL: 067092 FRAME: 0819

BLUE-0928P	Owned by Zeventy	EP 1888880.0	372387	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	06/11/2020	PUBLISHED	
BLUE-0928K	Owned by Zeventy	HK 62021028403.5	40036635	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	03/29/2021	PUBLISHED	
BLUE-0921L	Owned by Zeventy	IL 275079	275079	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	06/02/2020	PUBLISHED	
BLUE-0928R	Owned by Zeventy	JP 20-2020-53280A	2021-506271	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	06/12/2020	PUBLISHED	
BLUE-0921R	Owned by Zeventy	KR 10-2020-7020128	10-2020-010336	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	07/13/2020	PUBLISHED	
BLUE-0921P	Owned by Zeventy	US 62/598923	WO 2019/118895	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	12/14/2017	CONV. COMPLETE	12/14/2018
BLUE-0921C	Owned by Zeventy	WO PCT/US2018/065786	US-2020-0392204-A1	DABIC INTER. ELIXIN RECEPTORS	12/14/2017	12/14/2018	ALLOWED	

Zeventy Ref.	BLUE-0986P	Owned by Zeventy	EP 1978656.4	3781188	ADAPTIVE CELLULAR THERAPY	06/13/2018	10/21/2020	ABANDONED	
	BLUE-0986T	Owned by Zeventy	US 62/657388	WO 2019/200316	ADAPTIVE CELLULAR THERAPY	06/13/2018	04/13/2018	CONV. COMPLETE	04/13/2019
	BLUE-0981C	Owned by Zeventy	WO PCT/US2019/072317	US-2021-0252084-A1	ADAPTIVE CELLULAR THERAPY	06/13/2018	04/12/2019	COMPLETED	
	BLUE-0981SFC	Owned by Zeventy	US 17/06466			06/13/2018	10/09/2020	ALLOWED	

Zeventy Ref.	BLUE-1014Z	Owned by Zeventy	NZ 771249	771249	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/17/2020	PUBLISHED	
	BLUE-1014U	Owned by Zeventy	AU 2019287720	2019287720	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/17/2020	PUBLISHED	
	BLUE-1018R	Owned by Zeventy	BR 88112020005439-8	BR112020205439-8	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/27/2020	PUBLISHED	
	BLUE-101CA	Owned by Zeventy	CA 3110636	3110636	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/07/2020	PUBLISHED	
	BLUE-101CN	Owned by Zeventy	CN 201980045973.5	112368021	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/07/2021	PUBLISHED	
	BLUE-101EP	Owned by Zeventy	EP 198139809.5	3806903	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/06/2021	PUBLISHED	
	BLUE-101E2	Owned by Zeventy	EP 24150405.90	40052400	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/04/2024	FILED	
	BLUE-101HK	Owned by Zeventy	HK 62021040649.7	40052400	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/09/2020	PUBLISHED	
	BLUE-101PL	Owned by Zeventy	IL 279310	279310	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	10/18/2021	PUBLISHED	
	BLUE-101P	Owned by Zeventy	JP 2020-569179	2021-527409	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/11/2020	PUBLISHED	
	BLUE-101KR	Owned by Zeventy	KR 10-2021-7000376	10-2021-7000376	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	01/06/2021	PUBLISHED	
	BLUE-101P1	Owned by Zeventy	US 62/685078	WO 2019/241685	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	06/14/2018	CONV. COMPLETE	06/14/2019
	BLUE-101PC	Owned by Zeventy	WO PCT/US2019/037270	WO 2019/241685	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	06/14/2019	COMPLETED	
	BLUE-101S6	Owned by Zeventy	SG 112020121558	112020121558	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/07/2020	PUBLISHED	
	BLUE-101USFC	Owned by Zeventy	US 16/973879	US-2021-0261659-A1	CD79A CHIMERIC ANTIGEN RECEPTORS	06/14/2018	12/10/2020	PUBLISHED	

Zeventy Ref.	BLUE-1034K	Owned by Zeventy	HK 6202054426.1	40065363A	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/22/2019	06/01/2022	ABANDONED	
	BLUE-1034U	Owned by Zeventy	AU 20202011990	2020211990	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/23/2019	07/22/2021	ABANDONED	01/22/2040
	BLUE-1082N	Owned by Zeventy	CN 202080016565.2	114206103	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/24/2019	01/22/2020	ABANDONED	
	BLUE-1088P	Owned by Zeventy	EP 2017488242	3914067	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/26/2019	06/26/2021	ABANDONED	
	BLUE-1091P	Owned by Zeventy	JP 2021-543180	2021-523044	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/26/2019	07/26/2021	ABANDONED	01/22/2020
	BLUE-1091S	Owned by Zeventy	US 17/773513	US-2021-0152034-A1	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/29/2019	01/22/2020	COMPLETED	
	BLUE-1092C	Owned by Zeventy	WO PCT/US2019/014668	WO 2020/154445	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/29/2019	01/22/2020	COMPLETED	
	BLUE-1093SFC	Owned by Zeventy	US 17/453309	US-2021-01086510-A1	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/29/2019	07/22/2021	PUBLISHED	

Zeventy Ref.	BLUE-1124K	Owned by Zeventy	HK 6202054426.1	40065363A	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/22/2019	06/01/2022	ABANDONED	
	BLUE-1104U	Owned by Zeventy	AU 20202011990	2020211990	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/23/2019	07/22/2021	ABANDONED	01/22/2040
	BLUE-1108N	Owned by Zeventy	CN 202080016565.2	114206103	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/24/2019	01/22/2020	ABANDONED	
	BLUE-1108P	Owned by Zeventy	EP 2017488242	3914067	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/26/2019	06/26/2021	ABANDONED	
	BLUE-1126P	Owned by Zeventy	JP 2021-543180	2021-523044	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/26/2019	07/26/2021	ABANDONED	01/22/2020
	BLUE-1126C	Owned by Zeventy	US 17/773513	US-2021-0152034-A1	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/29/2019	01/22/2020	COMPLETED	
	BLUE-1126SFC	Owned by Zeventy	WO PCT/US2019/014668	WO 2020/154445	METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS	01/29/2019	07/22/2021	PUBLISHED	

Zeventy Ref.	BLUE-111P1	Owned by Zeventy	US 62/779882	WO 2020/123933	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/14/2018	CONV. COMPLETE	12/14/2019
	BLUE-112PC	Owned by Zeventy	WO PCT/US2019/065216	WO 2020/123933	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019	COMPLETED	
	BLUE-111USFC	Owned by Zeventy	US 17/311767		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/08/2021	PENDING	

Zeventy Ref.	BLUE-1124K	Owned by Zeventy	HK 6202054426.1	40065301 A	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	04/19/2022	PUBLISHED	
	BLUE-1124U	Owned by Zeventy	AU 2019397152	2019397152	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021	ABANDONED	12/13/2039
	BLUE-112CA	Owned by Zeventy	CA 3121942	3121942	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/02/2021	ABANDONED	
	BLUE-112CN	Owned by Zeventy	CN 20198009008.3	113412276	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/27/2021	ABANDONED	
	BLUE-112EP	Owned by Zeventy	EP 19896079.1	3894436	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/08/2021	ABANDONED	
	BLUE-112P1	Owned by Zeventy	JP 2021-535329	2022-512475	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/11/2021	ABANDONED	12/14/2019
	BLUE-112P2	Owned by Zeventy	US 62/779889	WO 2021-012475	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	12/14/2018	CONV. COMPLETE	04/18/2020
	BLUE-112PC	Owned by Zeventy	US 62/835658	WO 2020/123936	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	04/18/2019	CONV. COMPLETE	
	BLUE-121USFC	Owned by Zeventy	WO PCT/US2019/065219	WO 2020/123936	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019	COMPLETED	
	BLUE-121USFC	Owned by Zeventy	US 17/311776		DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/08/2021	PENDING	

Zeventy Ref.	BLUE-1134K	Owned by Zeventy	HK 6202054426.1	40065302	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	04/19/2022	PUBLISHED	
	BLUE-1134U	Owned by Zeventy	AU 2019396533	2019396533	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021	PUBLISHED	12/13/2039
	BLUE-113CA	Owned by Zeventy	CA 3123804	3123804	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/01/2021	PUBLISHED	
	BLUE-113CN	Owned by Zeventy	CN 20198009008.3	113412276	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/27/2021	PUBLISHED	
	BLUE-113EP	Owned by Zeventy	EP 19896079.1	3894436	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/08/2021	PUBLISHED	
	BLUE-113P	Owned by Zeventy	IL 283897	283897	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/10/2021	PUBLISHED	
	BLUE-113R	Owned by Zeventy	JP 2021-535330	2022-513460	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/11/2021	PUBLISHED	
	BLUE-113R	Owned by Zeventy	KR 10-2021-7021031	10-2021-0104772	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	07/09/2021	PUBLISHED	
	BLUE-113P2	Owned by Zeventy	US 62/779971	WO 2020/123937	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	12/14/2018	CONV. COMPLETE	04/08/2020
	BLUE-113PC	Owned by Zeventy	US 62/835659	WO 2020/123938	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	04/08/2019	CONV. COMPLETE	
	BLUE-131USFC	Owned by Zeventy	WO PCT/US2019/065223	WO 2020/123938	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019	COMPLETED	
	BLUE-131USFC	Owned by Zeventy	US 17/312120	US-2022-0031750-A1	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021	PUBLISHED	

Zeventy Ref.	BLUE-114P1	Owned by Zeventy	US 62/779953	WO 2020/123947	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2018	12/14/2018	CONV. COMPLETE	04/18/2020
	BLUE-114P2	Owned by Zeventy	US 62/835662	WO 2020/123947	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	04/18/2019	04/18/2019	CONV. COMPLETE	04/18/2020
	BLUE-114PC	Owned by Zeventy	WO PCT/US2019/065241	US-2022-0025014-A1	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	12/13/2019	COMPLETED	
	BLUE-114USFC	Owned by Zeventy	US 17/312116	US-2022-0025014-A1	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES	12/14/2018	06/09/2021	PUBLISHED	

Zeventy Ref.	Inventors	CO	Serial No.	Publication No.	Application Title	Priority Date	Filing Date	Issue Date	Status	Expiration Date
BLUE-1154U	Co-Owned Medigen/Zeventy	AU	2020249596.00		MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PENDING	
BLUE-1154R	Co-Owned Medigen/Zeventy	BR	8811202019066-0	BR112021019066-0 A2	MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115CA	Co-Owned Medigen/Zeventy	CA	3134076.00	3134076	MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115CL	Co-Owned Medigen/Zeventy	CL	202102491.00		MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115CN	Co-Owned Medigen/Zeventy	CN	202080039542.40	CN 114126716 A	MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115CO	Co-Owned Medigen/Zeventy	CO	N2020010012587	20210012587	MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	
BLUE-115EA	Co-Owned Medigen/Zeventy	EA	202192327.00	202192327	MAGE M4 T CELL RECEPTORS	03/27/2019	03/27/2020		PUBLISHED	

BLUE-1231P
Owned by Zseventy

BLUE-123KR
Owned by Zseventy

BLUE-123MX
Owned by Zseventy

BLUE-123NZ
Owned by Zseventy

BLUE-123P1
Owned by Zseventy

BLUE-123PC
Owned by Zseventy

BLUE-123SG2
Owned by Zseventy

BLUE-123USPC
Owned by Zseventy

JP 2021-573844 2022-597159 COMPOSITIONS AND METHODS FOR TREATING CANCER

KR 10-2022-70013201 10-2022-0033485 COMPOSITIONS AND METHODS FOR TREATING CANCER

MX 10-2022-70013201 10-2022-0033485 COMPOSITIONS AND METHODS FOR TREATING CANCER

NA 10-2022-70013201 10-2022-0033485 COMPOSITIONS AND METHODS FOR TREATING CANCER

NZ 784226 784226 COMPOSITIONS AND METHODS FOR TREATING CANCER

US 62/968188 COMPOSITIONS AND METHODS FOR TREATING CANCER

US 62/991314 COMPOSITIONS AND METHODS FOR TREATING CANCER

WO PCT/US2020/037145 WO 2020/252110 COMPOSITIONS AND METHODS FOR TREATING CANCER

SG 11202113613V COMPOSITIONS AND METHODS FOR TREATING CANCER

US 17/618747 US-2022-0280957-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER

Zseventy Ref.
BLUE-129T1
Owned by Zseventy

BLUE-1250S
Owned by Zseventy

Application Title
CELL CULTURE MEDIUM
CELL CULTURE MEDIUM

Status
CONV COMPLETE
ALLOWED

Expiration Date
10/25/2020

Zseventy Ref.
BLUE-127CA
Owned by Zseventy

BLUE-127CA
Owned by Zseventy

BLUE-127CN
Owned by Zseventy

BLUE-127HP
Owned by Zseventy

BLUE-127HK
Owned by Zseventy

BLUE-127P1
Owned by Zseventy

BLUE-127YR
Owned by Zseventy

BLUE-127Y1
Owned by Zseventy

BLUE-127USC
Owned by Zseventy

Priority Date
04/17/2020
04/17/2020
04/17/2020
04/17/2020
04/17/2020
04/17/2020
04/17/2020
04/17/2020
04/17/2020

Filing Date
10/19/2022
10/14/2022
10/13/2022
11/04/2022
07/12/2023
10/14/2022
10/11/2022
04/17/2020
04/17/2020

Issue Date
04/16/2021
04/16/2021
04/16/2021
04/16/2021
04/16/2021
04/16/2021
04/16/2021
04/16/2021
04/16/2021

Status
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING

Expiration Date
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
04/17/2021
04/17/2021

Zseventy Ref.
BLUE-128AU
Owned by Zseventy

BLUE-128CA
Owned by Zseventy

BLUE-128CN
Owned by Zseventy

BLUE-128HP
Owned by Zseventy

BLUE-128HK
Owned by Zseventy

BLUE-128P1
Owned by Zseventy

BLUE-128YR
Owned by Zseventy

BLUE-128Y1
Owned by Zseventy

BLUE-128USC
Owned by Zseventy

BLUE-128USPC
Owned by Zseventy

Priority Date
06/11/2020
06/11/2020
06/11/2020
06/11/2020
06/11/2020
06/11/2020
06/11/2020
06/11/2020
06/11/2020

Filing Date
11/28/2022
11/30/2022
11/25/2022
11/25/2022
11/24/2022
11/24/2022
11/24/2022
11/24/2022
12/08/2022

Issue Date
06/10/2021
06/10/2021
06/10/2021
06/10/2021
06/10/2021
06/10/2021
06/10/2021
06/10/2021
06/10/2021

Status
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING

Expiration Date
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041
06/10/2041

Zseventy Ref.
BLUE-129P1
Owned by Zseventy

BLUE-129PC
Owned by Zseventy

BLUE-129USPC
Owned by Zseventy

Application Title
FIB ANTIBODIES
FIB ANTIBODIES
FIB ANTIBODIES

Status
COMPLETED
PENDING
PENDING

Expiration Date
04/10/2021

Zseventy Ref.
BLUE-130AU
Owned by Zseventy

BLUE-130KR
Owned by Zseventy

BLUE-130CA
Owned by Zseventy

BLUE-130CN
Owned by Zseventy

BLUE-130HP
Owned by Zseventy

BLUE-130HK
Owned by Zseventy

BLUE-130P1
Owned by Zseventy

BLUE-130YR
Owned by Zseventy

BLUE-130Y1
Owned by Zseventy

BLUE-130USC
Owned by Zseventy

BLUE-130USPC
Owned by Zseventy

Priority Date
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020
03/27/2020

Filing Date
10/26/2022
10/26/2022
11/02/2022
10/27/2022
05/17/2023
09/26/2022
10/21/2022
10/21/2022
10/26/2022
03/26/2021
03/26/2021

Issue Date
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041
03/26/2041

Status
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING

Expiration Date
03/26/2041

Zseventy Ref.
BLUE-131AU
Owned by Zseventy

BLUE-131BR
Owned by Zseventy

BLUE-131CA
Owned by Zseventy

BLUE-131CN
Owned by Zseventy

BLUE-131HP
Owned by Zseventy

BLUE-131HK
Owned by Zseventy

BLUE-131P1
Owned by Zseventy

BLUE-131YR
Owned by Zseventy

BLUE-131Y1
Owned by Zseventy

BLUE-131USC
Owned by Zseventy

BLUE-131USPC
Owned by Zseventy

Priority Date
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020
08/25/2020

Filing Date
03/17/2023
02/23/2023
04/14/2023
03/02/2023
02/13/2023
02/13/2023
02/24/2023
03/15/2023
03/17/2023
08/25/2020
08/25/2020

Issue Date
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041
08/24/2041

Status
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING
PENDING

Expiration Date
08/24/2041

Zseventy Ref.
BLUE-140AU
Owned by Zseventy

BLUE-140BR
Owned by Zseventy

BLUE-140CA
Owned by Zseventy

Application Title
ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES
ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES
ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES

Status
PENDING
PENDING
PENDING

Expiration Date
07/14/2022

